Interpace Biosciences Earnings Roundup: Lucira Health, Interpace Biosciences, Lucid Diagnostics The diagnostics firms posted their quarterly financial results this week. In Brief This Week: Illumina, Interpace, Genetic Signatures, Guardant Health, More News items for the week of Aug. 29, 2022. Earnings Roundup: Lucira Health, T2 Biosystems, Interpace Biosciences Lucira Health, T2 Biosystems, and Interpace Biosciences reported quarterly financial results this week. Interpace Biosciences Posts 6 Percent Revenue Increase in Q1 The company said that it experienced improved reimbursement rates and clinical services volume for its thyroid cancer tests compared to Q1 of last year. Interpace Biosciences, Miroculus, Twist Bioscience Partner to Automate NGS Library Prep in Cancer Dx The three companies join forces to automate sample preparation for genetic testing of endocrine and GI cancers using digital microfluidics technology. Apr 1, 2022 Interpace Biosciences Reports 14 Percent Increase in Q4 Revenues Feb 22, 2022 Interpace Biosciences Says CMS to Cover Thyroid Tests, Reversing Earlier Decision Jan 31, 2022 CMS No Longer Reimbursing Interpace Bio Thyroid Tests; Firm's Rights Offering Terminated Jan 13, 2022 Interpace Commences $30M Rights Offering Nov 11, 2021 Interpace Biosciences Q3 Revenues Rise 15 Percent Aug 11, 2021 Interpace Biosciences Q2 Revenues More Than Double May 12, 2021 Interpace Biosciences Q1 Revenues Up 8 Percent Apr 22, 2021 Interpace Biosciences to Review Strategic Alternatives Apr 1, 2021 Interpace Biosciences Q4 Revenues More Than Double Feb 17, 2021 Interpace Biosciences Receives Nasdaq Delisting Notice, Initiates Restructuring Feb 1, 2021 Interpace, Rutgers, Mass General Sign Deal for Pancreatic Cyst Risk Assessment Biomarker Jan 20, 2021 Interpace Bio Q3 Revenues Rise 6 Percent Oct 20, 2020 Interpace Biosciences Q2 Revenues Decline 14 Percent Jun 26, 2020 Interpace Biosciences Q1 Revenues Rise 53 Percent Apr 23, 2020 Interpace Biosciences Q4 2019 Revenues Drop 29 Percent, Miss Analyst Predictions Jan 13, 2020 Interpace Biosciences to Sell $20M in Preferred Stock, Plans Reverse Stock Split Jan 6, 2020 Interpace Biosciences, University of North Carolina Launch Barrett's Esophagus Study Dec 20, 2019 Interpace Biosciences Expanding Beyond Dx, Cancer With Acquisition, Name Change Premium Nov 13, 2019 Interpace Diagnostics Reports 33 Percent Q3 Revenue Growth; Changes Name to Interpace Biosciences Oct 25, 2019 Cancer Genetics Settles Failed Merger Deal With NovellusDx; Receives $6M From Interpace Load More Breaking News Simple HealthKit Raises $8M in Series A Round Top Five Articles on GenomeWeb Last Week: Quantum-Si Layoffs, UBS Coverage Initiations, More LumiraDx Secures FDA Emergency Use Authorization, UK Approval for COVID-19, Flu Test Rarity Bioscience Raises Additional €500,000 Cancer Prognoses Informed by Module-Based Approach, Study Finds The Scan UK Team Presents Genetic, Epigenetic Sequencing Method Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers. DNA Biobank Developed for French Kidney Donors, Recipients The KiT-GENIE biobank described in the European Journal of Human Genetics contains DNA samples, genotyping profiles, immune patterns, and clinical features for thousands of kidney donors or transplant recipients in Nantes, France. Cardiometabolic Disease May Have Distinct Associations With Microbial Metabolites in Blood, Gut By analyzing gut microbes in combination with related metabolites in feces and blood, researchers in Nature Communications found distinct cardiometabolic disease relationships at each site. Study Reveals New Details About Genetics of Major Cause of Female Infertility Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.